icon-folder.gif   Conference Reports for NATAP  
 
  64rd Annual Meeting of the
American Association for the
Study of Liver Diseases
Washington, DC Nov 1-5 2013
Back grey_arrow_rt.gif
 
 
 
Twenty-Eight Day Safety and Efficacy of Tenofovir Alafenamide (TAF) Fumarate in Chronic Hepatitis B (CHB) Patients
 
 
  Reported by Jules Levin
AASLD Nov 1-5 2013 Wash DC
 
Kosh Agarwal,1 Scott K. Fung,2 Tuan T. Nguyen,3 Wendy Cheng,4 Eric Sicard,5 Stephen D. Ryder,6 John F. Flaherty,7 Eileen Lawson,7 Sally Zhao,7 Mani Subramanian,7 John G. McHutchison,7 Edward J. Gane,8 Graham R. Foster9
1Institute of Liver Studies, Kings College Hospital, London, United Kingdom; 2Toronto General Hospital, Toronto, Ontario, Canada; 3T. Nguyen Research and Education, San Diego, CA; 4Royal Perth Hospital, Perth, Western Australia, Australia; 5Algorithme Pharma, Montreal, Quebec, Canada;
6Nottingham University Hospitals NHS Trust and Biomedical Research Unit, Nottingham, United Kingdom; 7Gilead Sciences, Inc., Foster City, CA; 8Auckland Clinical Studies, Auckland, New Zealand; 9Queen Mary's University of London, Barts Health, United Kingdom

AASLD1.gif

AASLD2.gif

AASLD3.gif

AASLD4.gif

AASLD5.gif

AASLD6.gif

AASLD7.gif

AASLD8.gif